CellMax Life

Founded in 2013 and headquartered in Sunnyvale, US, CellMax Life focuses on advanced solutions for colorectal cancer screening.CellMax Life specializes in innovative solutions for colorectal cancer screening and prevention, with a primary focus on their flagship product, FirstSight™, which is recognized as the first blood test designed specifically for adenoma detection. This proprietary blood test functions by identifying precancerous polyps, known as adenomas, which are critical to monitor as their removal has been shown to reduce colorectal cancer mortality by 53%. The company targets a substantial client base, including healthcare providers and institutions that follow national guidelines recommending routine screenings for over 125 million Americans. CellMax Life's products are primarily marketed in the United States, complemented by operations in Taiwan, thereby addressing a global audience concerned with colorectal cancer prevention and early detection.CellMax Life generates revenue through the direct provision of its FirstSight™ blood test to healthcare providers and facilities that incorporate it into their routine screening protocols. The business model involves partnerships with medical institutions, enabling them to offer this innovative screening solution to their patients. Revenue transactions are structured around service agreements with these providers, where the test is administered to patients, and results are analyzed and reported back to the healthcare professionals. This operational setup allows for streamlined processes in testing and result dissemination, ensuring that patients receive timely information regarding their health status.CellMax Life aims to expand its product offerings and market presence. The company is focused on developing additional innovative screening products designed to enhance early detection capabilities.00 mn, CellMax Life plans to enhance its marketing efforts and expand into new geographic markets, specifically targeting additional regions within the US and potentially expanding its operations further in Taiwan by the end of 2017.

1. Series A

   Jul 26, 2016

   Amount

   $9M

   Investors

   Locked

2. Series A

   Jun 1, 2013

   Amount

   $5M

   Investors

   Locked